TRANSGENE (EPA:TNG) | Finanzwire

Basculer en Français

10597	Companies
224776	Keywords
153510	Articles
118925	Press releases

Home
Companies
TRANSGENE

PRESS RELEASE

published on 03/27/2025 at 17:45, 1 year 2 months ago

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025
Transgene achieves key milestones in 2024, including clinical proof of principle for individualized cancer vaccine TG4050, with strong outlook for 2025. New trial planned in Q4 2025 for a second indication

Milestones Cancer Vaccine Transgene 2025 Outlook Clinical Proof
BRIEF

published on 01/21/2025 at 17:50, 1 year 4 months ago

Transgene Prepares for Biomed Investor Forum

Investors BIOMED Forum Immunotherapy Transgene Viral Vectors
PRESS RELEASE

published on 01/21/2025 at 17:45, 1 year 4 months ago

Transgene to Participate in the Biomed Forum Investor Conference
Transgene's management team to participate in the Biomed Forum Investor Conference in Paris on February 4, 2025

Investor Conference Paris BIOMED Forum Transgene February 4
BRIEF

published on 11/05/2024 at 07:35, 1 year 7 months ago

Transgene and ProBioGen join forces for personalized cancer vaccines

Biotechnology Cancer Transgene ProBioGen Personalized Vaccines
PRESS RELEASE

published on 10/14/2024 at 07:30, 1 year 8 months ago

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
BRIEF

published on 09/14/2024 at 09:10, 1 year 9 months ago

Transgene and BioInvent: promising results for the oncolytic virus BT-001

Cancer Transgene Oncolytic Virus BioInvent BT-001
PRESS RELEASE

published on 09/14/2024 at 09:05, 1 year 9 months ago

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
Transgene and BioInvent present promising early results of oncolytic virus BT-001 in ESMO 2024, showing antitumor activity in solid tumors. BT-001 induces tumor regression and enhances T cell infiltration

Transgene Oncolytic Virus BioInvent Antitumor Activity ESMO 2024
BRIEF

published on 09/13/2024 at 10:37, 1 year 9 months ago

Threshold crossing by SITAM Belgium in TRANSGENE SA

Voting Rights Capital Increase Threshold Crossing SITAM Belgium TRANSGENE SA
BRIEF

published on 09/10/2024 at 07:35, 1 year 9 months ago

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Cancer Treatment Oncology Leadership Immunotherapy Transgene
PRESS RELEASE

published on 09/10/2024 at 07:30, 1 year 9 months ago

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Transgene appoints Dr. Emmanuelle Dochy as CMO and Dr. Maurizio Ceppi as CSO to drive innovation in cancer immunotherapies. Company progresses clinical pipeline with therapeutic vaccine TG4050

Innovation Oncology Clinical Pipeline Immunotherapy Transgene

Accesswire

Published on 06/18/2026 at 18:00, 2 hours 14 minutes ago

BEACN Closes Second Series Under Loan Program and Previews BEACN App Version 1.4
Published on 06/18/2026 at 17:30, 2 hours 44 minutes ago

Sekur Private Data Appoints Nathan R. Price as Special Advisor for Diplomacy & Intelligence
Published on 06/18/2026 at 15:50, 4 hours 24 minutes ago

Pentagon I Capital Corp. and Prospectiva Resources Ltd. Announce Financing
Published on 06/18/2026 at 15:00, 5 hours 14 minutes ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Published on 06/18/2026 at 14:30, 5 hours 44 minutes ago

Voting Results from Solitario Resources Corp Annual Meeting Held June 17, 2026

View all ACCESSWIRE

EQS Group

Published on 06/18/2026 at 18:55, 1 hour 19 minutes ago

Holding(s) in Company
Published on 06/18/2026 at 18:55, 1 hour 19 minutes ago

Holding(s) in Company
Published on 06/18/2026 at 18:30, 1 hour 43 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/18/2026 at 18:25, 1 hour 48 minutes ago

Sopra Steria achives Level 2 Responsible Digital Label and strengthens its responsible digital strategy
Published on 06/18/2026 at 17:45, 2 hours 29 minutes ago

2CRSi SA: 2CRSi disputes the content of the document published by Grizzly Research and is preparing a substantiated response calling for the suspension of trading in its shares

Les Echos

Published on 06/18/2026 at 18:00, 2 hours 14 minutes ago

Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 2 hours 29 minutes ago

EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 2 hours 35 minutes ago

Statement of transactions in own shares from June 8, 2026 to June 12, 2026
Published on 06/18/2026 at 13:00, 7 hours 14 minutes ago

Edenred statement
Published on 06/18/2026 at 09:06, 11 hours 8 minutes ago

Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany

View all LES ECHOS COMFI WIRE